Simply Wall St.2d agoneutral
Halozyme Therapeutics (HALO) Following Record Results And Higher Guidance Is The Stock Still UndervaluedNews
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
107last 24h
3127last 7d
512● bullish (7d)
311● bearish (7d)
227publishers
GuruFocus.com2d agoneutral
Halozyme Stocks Slip 4.28% Despite 39% Revenue Growth and Modestly Higher GuidanceSimply Wall St.2d agobullish
Halozyme Stock Jumps On Strong Earnings But Guidance Reset Raises QuestionsGuruFocus.com2d agoneutral
Halozyme Therapeutics Inc (HALO) (Q3 2026) Earnings Call Highlights: Record Revenue, Raised ...MT Newswires3d agoneutral
Halozyme Therapeutics Q3 Adjusted Earnings, Revenue Rise; 2026 Guidance LiftedStockStory3d agobearish
Halozyme Therapeutics (NASDAQ:HALO) surprises with Q3 2026 sales but stock dropsPR Newswire3d agoneutral
HALOZYME REPORTS THIRD QUARTER 2026 RESULTS AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCEInsider Monkey10d agoneutral
Exelixis (EXEL) vs. BMRN and NBIX: Can CABOMETYX and Pipeline Growth Revive Investor Confidence?Insider Monkey12d agoneutral
Strong Royalties and New Launches Accelerate Halozyme Therapeutics’ (HALO) Growth MomentumBusiness Wire12d agoneutral
Brilliant Labs Launches Halo Glasses, A New Generation of Privacy-First Smartglasses